In asubscription model, payers agree to a fixed cost to access aparticular drug over a set period of time. (Photo:Shutterstock)
Medicaid programs in Louisiana and Washington have pioneered theuse of prescription drug subscriptions for newhepatitis C pharmaceuticals, with a goal of expanding patientaccess and containing costs.
But a new report by the RAND Corporation cautions that drugsubscription models are relatively new and untested, and they maynot ultimately reduce costs for public and private payers. Payerscould end up spending more under drug subscriptions than they dowith the traditional cost-per-unit models, the paper argues.Moreover, private payers and Medicare drug plans cannot implementdrug subscriptions without regulatory changes, it notes. But thewider push toward value-based health care means that drugsubscriptions may be an area of growth.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Karen Sloan
Karen Sloan is the Legal Education Editor and Senior Writer at ALM. Contact her at [email protected]. On Twitter: @KarenSloanNLJ Sign up for Ahead of the Curve—her weekly email update on trends and innovation in legal education—here: https://www.law.com/briefings/ahead-of-the-curve/
